View Older Stories View More Recent Stories

Dec 15, 2023 08:30AM Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
Dec 6, 2023 04:08PM Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
Nov 22, 2023 08:30AM Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
Nov 9, 2023 07:30AM Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 3, 2023 04:05PM Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
Sep 28, 2023 04:17PM WAVE Life Sciences (WVE) Highlights Growth Strategy
Sep 28, 2023 04:15PM Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
Sep 28, 2023 04:15PM Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
Sep 25, 2023 08:30AM Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
Sep 6, 2023 08:30AM Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 5, 2023 07:31AM WAVE Life Sciences (WVE) submits first clinical trial application for WVE-006 in AATD
Sep 5, 2023 07:30AM Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
Sep 5, 2023 07:30AM Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
Aug 3, 2023 07:30AM Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Jul 27, 2023 08:30AM Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
Jun 26, 2023 08:44AM WAVE Life Sciences (WVE) Joins the Russell 2000 and Russell 3000 Indexes
Jun 26, 2023 08:30AM Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
May 23, 2023 07:31AM WAVE Life Sciences (WVE) Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004, to Discontinue Development
May 23, 2023 07:30AM Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
May 16, 2023 08:30AM Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
May 3, 2023 07:30AM Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
Apr 26, 2023 08:30AM Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
Apr 26, 2023 08:30AM Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
Apr 20, 2023 08:30AM Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Apr 20, 2023 08:30AM Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Mar 29, 2023 08:00AM Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
Mar 29, 2023 08:00AM Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
Mar 22, 2023 07:30AM Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Mar 22, 2023 07:30AM Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Mar 2, 2023 08:30AM Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
Mar 2, 2023 08:30AM Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
Feb 9, 2023 04:05PM Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
Feb 9, 2023 04:05PM Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
Dec 19, 2022 07:38AM WAVE Life Sciences (WVE) Reports Provides Positive Update on Proof-of-Concept Study for WVE-N531
Dec 19, 2022 07:37AM Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
Dec 19, 2022 07:37AM Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
Dec 13, 2022 07:31AM Wave Life Sciences (WVE) and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Dec 13, 2022 07:30AM Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Dec 13, 2022 07:30AM Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Nov 10, 2022 07:30AM Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 10, 2022 07:30AM Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 9, 2022 08:30AM Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
Nov 9, 2022 08:30AM Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
Nov 3, 2022 08:30AM Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
Nov 3, 2022 08:30AM Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
Oct 3, 2022 08:30AM Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
Oct 3, 2022 08:30AM Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
Sep 28, 2022 01:30PM WAVE Life Sciences (WVE) Highlights Therapeutic Potential for WVE-006
Sep 28, 2022 01:30PM Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
Sep 28, 2022 01:30PM Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
View More Recent Stories View Older Stories